Mid-sized biotech companies face a unique set of challenges. You’re trying to advance several programs in parallel, but you want to keep your teams small and agile to maintain your competitive and innovative edge. When you’re faced with resource constraints, or a problem you can’t address with your in-house capabilities, you need a partner that can not only keep pace with your team, but also perform at the level of scientific excellence that you demand.
When Jeff, the R&D director at a mid-sized biotech company, finds out that his program is threatened by negative clinical trial data, can his team demonstrate that their backup molecule is differentiated enough to continue their work before it’s too late?
- Navigating the World of Preclinical CROs: Where to Start and How to Focus
- Designing a Novel Cancer Drug: From Hit ID to Candidate
- In Search of a Disease-Modifying Agent for Parkinson’s Disease
- High-Throughput Screening: An Insider's Guide to Outsourcing